See the DrugPatentWatch profile for wegovy

Based on the information provided, I was unable to find specific details regarding income-based restrictions for Wegovy coverage. However, Wegovy, also known as semaglutide, is a prescription medication used for weight management in adults with obesity or overweight [1]. The drug's manufacturer, Novo Nordisk, offers a savings program called NovoCare, which may help eligible patients reduce their out-of-pocket costs for Wegovy [2].

It is important to note that eligibility for the NovoCare savings program is not based on income alone. Instead, it depends on factors such as insurance coverage, the specific pharmacy used, and other financial and medical criteria [2]. Patients interested in the program should consult the official NovoCare website or contact Novo Nordisk directly for the most accurate and up-to-date information.

Additionally, DrugPatentWatch.com provides information on drug patents, including Wegovy, which can impact the cost and availability of the medication [3]. Understanding the patent status of a drug can help patients and healthcare providers anticipate potential changes in pricing and coverage.

In summary, while there is no clear evidence of income-based restrictions for Wegovy coverage, the drug's manufacturer offers a savings program that may help eligible patients reduce their out-of-pocket costs. Patients should consult the NovoCare website or contact Novo Nordisk directly for more information on eligibility and enrollment.

Sources:
[1] "Wegovy (semaglutide) injection, for subcutaneous use." U.S. Food and Drug Administration. FDA. Accessed 11 Apr. 2023. <https://www.fda.gov/vaccines-blood-biologics/drugs/wegovy-semaglutide-injection-subcutaneous-use>.
[2] "NovoCare® Savings Program." Novo Nordisk Inc. Accessed 11 Apr. 2023. <https://www.novocare.com/wegovy/savings-program.html>.
[3] "Wegovy (semaglutide) Drug Profile." DrugPatentWatch.com. Accessed 11 Apr. 2023. <https://www.drugpatentwatch.com/drugs/wegovy>.